Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial
Zhou Q, Wang Z, Wang H, Chen Z, Li X, Dai X, Zhang Y, Yu X, Zhou R, Hu W. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American Journal Of Cardiovascular Drugs 2023, 23: 101-112. PMID: 36622539, DOI: 10.1007/s40256-022-00562-5.Peer-Reviewed Original ResearchConceptsHealthy Chinese volunteersMultiple ascending dosesChinese volunteersDose titrationAdverse eventsPharmacodynamic profileSequential cohortsDose-escalation phase I trialTarget international normalized ratioTreatment-related adverse eventsSerious adverse eventsPhase I trialInternational normalized ratioTarget rangeHealthy Chinese populationAscending dosesI trialNormalized ratioStable anticoagulationTecarfarinCohortChinese populationTolerabilityEarly withdrawalVolunteers